Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus

Mol Genet Metab. 2012 Mar;105(3):525-7. doi: 10.1016/j.ymgme.2011.12.020. Epub 2012 Jan 4.

Abstract

KCNJ11 polymorphisms have been linked to the risk of developing type 2 diabetes. Our aim was to define the contribution of KCNJ11 to new-onset diabetes after transplantation (NODAT) among patients treated with Tacrolimus (Tac). A total of 115 NODAT and 205 non-NODAT were genotyped for rs5219 (p.E23K). AA+AG genotypes were significantly associated with NODAT-risk (p=0.004; OR=2.10). The reported effect of this KCNJ11 polymorphism on insulin release by beta cells could explain this association.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Calcineurin Inhibitors
  • Diabetes Mellitus, Type 2 / chemically induced*
  • Diabetes Mellitus, Type 2 / genetics*
  • Female
  • Genotype
  • Heart Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Insulin / metabolism
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Potassium Channels, Inwardly Rectifying / genetics*
  • Tacrolimus / adverse effects*
  • Tacrolimus / therapeutic use
  • Young Adult

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Insulin
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • Tacrolimus